UK biotech Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion.  The companies say the acquisition advances antibody-drug conjugate (ADC) innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets and next-generation first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform, having potential impact across multiple solid tumour settings.  Myricx Bio was […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!